What is the current stock price of Kiora Pharmaceuticals, Inc. (KPRX)?

As of the latest market data, Kiora Pharmaceuticals, Inc. (KPRX) is trading at $2.47. The stock has seen a loss of -0.40% today.

Does Kiora Pharmaceuticals, Inc. (KPRX) pay a dividend?

Based on current data, Kiora Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Kiora Pharmaceuticals, Inc.?

The current market capitalization of Kiora Pharmaceuticals, Inc. (KPRX) is approximately unavailable.

KPRX

Kiora Pharmaceuticals, Inc.·Healthcare

2.47

0.403%(−0.01)

Market Closed

2.76

11.741%(+0.29)

After Hours

Last Updated: — ET

52W L: $1.7652W H: $4.18

KPRX NEWS

newsfilecorp.com

Apr 2

Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D.

newsfilecorp.com

Mar 25

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases. Key fourth-quarter, full-year 2025, and recent corporate highlights include: Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2 randomized, controlled clinical trial in patients with advanced retinitis pigmentosa.

newsfilecorp.com

Feb 19

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section.

defenseworld.net

Feb 9

Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)

Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation. Profitability This table compares Stevanato Group and Kiora

newsfilecorp.com

Jan 27

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs.

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2015-02-13

Beta

-0.77

Websitewww.kiorapharma.com↗